Cipla to Distribute Sanofi’s CNS Products in India
Cipla to distribute Sanofi India’s central nervous system product range in India
Overview
Sanofi India Limited (SIL) and Sanofi Healthcare India Private Limited and Cipla Limited (Cipla) announced an exclusive partnership for distribution and promotion of Sanofi India’s central nervous system (CNS) product range in India.
Responsibilities Post Partnership
As a part of this partnership, Cipla will be responsible for the distribution of Sanofi India’s six CNS brands including Frisium, a leading brand in the anti-epileptic medication category.
While Sanofi India will continue to own, import, and manufacture its complete range of CNS products across plants in India and internationally, Cipla will leverage its capabilities and robust India-wide network of strong marketing and sales professionals, distributors, institutions, and market outreach programs to expand access to these treatments for patients who need them.
Words from Sanofi India
Mr. Rodolfo Hrosz, managing director, Sanofi India Limited, said: “Sanofi India’s CNS products are leaders in their respective categories. These well-established brands already improve lives of many patients across urban centres in the country. Cipla’s wide presence will enable us to expand the reach of this portfolio to healthcare professionals and patients across all India.”
Words from CEO: Cipla Limited
Achin Gupta, chief executive officer – One India Business, Cipla Limited, said: “Enhancing access to high quality treatments is central to our purpose of ‘Caring for Life’. We are pleased to collaborate with Sanofi India to enhance accessibility to highly efficacious and quality therapeutic solutions in CNS and bring value to patients across the country. Central nervous system is one of the most challenging areas in medicine, and we believe this partnership is a significant step forward to address unmet needs of patients.”
Sanofi’s Innovative Pipeline
Sanofi India continues to focus on accelerating its strong innovation pipeline into India, across multiple therapeutic areas including diabetes, transplants, rare diseases, consumer healthcare and vaccines.
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!